LOS ANGELES, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases today announced that company management will hold a conference call to discuss second quarter 2015 business highlights and financial results at 4:30 p.m. EDT, August 13, 2015.
Access to the live webcast and teleconference is provided below:
- Domestic dial-in: 1-877-407-4018
- International dial-in: 1-201-689-8471
- Webcast: http://capricor.com/news/events/
A telephone replay of the call will be available by dialing 877-870-5176 for domestic callers or 858-384-5517 for international callers and entering the conference code: 13617105. The conference call webcast will be archived for approximately 90 days and will be available at http://capricor.com/news/events/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: CAP-1002, a cardiac cell therapy and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com.
CONTACT: Corporate Contact Capricor Therapeutics, Inc. AJ Bergmann, Vice President of Finance +1-310-358-3200 firstname.lastname@example.org Media Relations Russo Partners Christopher Hippolyte +1-646-942-5634 email@example.com Tony Russo, Ph.D. +1-212-845-4251 firstname.lastname@example.org Investor Relations: Russo Partners Robert Flamm, Ph.D. +1-212-845-4226 email@example.com